Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Open access
Bar-On, Yotam, Gruell, Henning, Schoofs, Till, Pai, Joy A., Nogueira, Lilian, Butler, Allison L., Millard, Katrina, Lehmann, Clara, Suárez, Isabelle, Oliveira, Thiago Y., Karagounis, Theodora, Cohen, Yehuda Z., Wyen, Christoph, Scholten, Stefan, Handl, Lisa, Belblidia, Shiraz, Dizon, Juan P., Vehreschild, Jörg J., Witmer-Pack, Maggi, Shimeliovich, Irina, Jain, Kanika, Fiddike, Kerstin, Seaton, Kelly E., Yates, Nicole L., Horowitz, Jill, Gulick, Roy M., Pfeifer, Nico, Tomaras, Georgia D., Seaman, Michael S., Fätkenheuer, Gerd, Caskey, Marina, Klein, Florian, Nussenzweig, Michel C.·2018·Nature Medicine

Abstract

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone HIV-1 replication leads to the production of drug-resistant viral variants1,2. Combinations of drugs can establish long-term control, however, antiretroviral therapy (ART) requires daily dosing, can cause side effects and does not eradicate the infection3,4. Although anti-HIV-1 antibodies constitute a potential alternative to ART5,6, treatment of viremic individuals with a single antibody also results in emergence of resistant viral variants7–9. Moreover, combinations of first-generation anti-HIV-1 broadly neutralizing antibodies (bNAbs) had little measurable effect on the infection10–12. Here we report on a phase 1b clinical trial (NCT02825797) in which two potent bNAbs, 3BNC11713 and 10-107414, were administered in combination to seven HIV-1 viremic individuals. Infusions of 30 mg kg−1 of each of the antibodies were well-tolerated. In the four individuals with dual antibody-sensitive viruses, immunotherapy resulted in an average reduction in HIV-1 viral load of 2.05 log10 copies per ml that remained significantly reduced for three months following the first of up to three infusions. In addition, none of these individuals developed resistance to both antibodies. Larger studies will be necessary to confirm the efficacy of antibody combinations in reducing HIV-1 viremia and limiting the emergence of resistant viral variants. Combination of two broadly neutralizing antibodies is effective in reducing HIV-1 viremia and in limiting the emergence of resistant viral variants in individuals harboring antibody-sensitive viruses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0186-4

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 251

Metadata

Authors
Bar-On, Y., Gruell, H., Schoofs, T., Pai, J. A., Nogueira, L., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Karagounis, T., Cohen, Y. Z., Wyen, C., Scholten, S., Handl, L., Belblidia, S., Dizon, J. P., Vehreschild, J. J., Witmer-Pack, M., Shimeliovich, I., Jain, K., Fiddike, K., Seaton, K. E., Yates, N. L., Horowitz, J., Gulick, R. M., Pfeifer, N., Tomaras, G. D., Seaman, M. S., Fätkenheuer, G., Caskey, M., Klein, F., & Nussenzweig, M. C.
Venue
Nature Medicine
Published
2018-09-26
Volume
24
Issue
11
Pages
1701-1707
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2892753696
Cited by
251
References
5
FWCI
16.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. https://app.cochat.ai/papers/10.1038/s41591-018-0186-4
The paper
Bar-On, Y., Gruell, H., Schoofs, T., Pai, J. A., Nogueira, L., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Karagounis, T., Cohen, Y. Z., Wyen, C., Scholten, S., Handl, L., Belblidia, S., Dizon, J. P., Vehreschild, J. J., Witmer-Pack, M., . . . Nussenzweig, M. C. (2018). Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine. https://doi.org/10.1038/s41591-018-0186-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.